The study is a multi-center, non-interventional, prospective observational study which enrols 2500 breast cancer patients from China county area. The purpose of this study is to be aware of the real-world data of the current breast cancer diagnosis and treatment model in the county. It aims to understand the gap between the county and the SOC in the diagnosis and treatment.

The study is a multi-center, non-interventional, prospective observational study which enrols 2500 breast cancer patients from China county area. The patients will be divided into four cohorts by HR/HER2 status and early/late stage without prespecified minimum or maximum limit of patient number for each cohort.

The potential study subjects will be identified by the investigators by face-to-face visit. During this process approximately 2500 subjects will be enrolled in 1 year. All subjects will be sign informed consent and recorded for demographic characteristics, medical history, treatment history, treatment hospital, pathologic diagnosis, receptor status, therapeutic regimen, etc at the beginning of enrollment. Normally, there will be 4 visits for EBC and 6 visits for ABC in hospitals during yearlong follow-up period. All visits are according to the standard frequency of clinical follow-up. If the patient does not come to the hospital for follow-up on a regular basis, we will follow-up by telephone inquiries, etc.The potential study subjects will be identified by the investigators by face-to-face visit. During this process approximately 2500 subjects will be enrolled in 1 year. All subjects will be sign informed consent and recorded for demographic characteristics, medical history, treatment history, treatment hospital, pathologic diagnosis, receptor status, therapeutic regimen, etc at the beginning of enrollment. Normally, there will be 4 visits for EBC and 6 visits for ABC in hospitals during yearlong follow-up period. All visits are according to the standard frequency of clinical follow-up. If the patient does not come to the hospital for follow-up on a regular basis, we will follow-up by telephone inquiries, etc.

Inclusion Criteria:

Cohort 1

• Age ≥ 18 years at the time of enrollment
• Histologically confirmed HER2+ breast cancer
• Newly diagnosed or completed definitive early breast surgery
• Complete medical history information

Cohort 2

• Age ≥ 18 years at the time of enrollment
• Histologically confirmed HR+ HER2- breast cancer
• Newly diagnosed or completed definitive early breast surgery
• Complete medical history information

Cohort 3

• Age ≥ 18 years at the time of enrollment
• Histologically confirmed HER2+ breast cancer
• De Novo or recurrent metastatic breast cancer
• Complete medical history information

Cohort 4

• Age ≥ 18 years at the time of enrollment
• Histologically confirmed HR+ HER2- breast cancer
• De Novo or recurrent metastatic breast cancer
• Complete medical history information

Exclusion Criteria:

Cohort 1

• Participated in other Intervention drug clinical trials within 4 weeks before admission Cohort 2
• Participated in other Intervention drug clinical trials within 4 weeks before admission Cohort 3
• Patients with HER2 + advanced breast cancer who have received more than 2 lines of therapy
• Participated in other Intervention drug clinical trials within 4 weeks before admission Cohort 4
• Patients with HR+ HER2- advanced breast cancer who have received more than 2 lines of therapy
• Participated in other Intervention drug clinical trials within 4 weeks before admission

A total of 2500 breast cancer patients will be recruited in this study. The entire subjects are spread over 13 Provinces (Henan province, Hebei province, Hunan Province etc.) and 2 autonomous regions (Inner Mongolia Autonomous Region and Guangxi Zhuang Autonomous Region). In order to acquire adequate treatment patterns choices in China county area. Data collection and analysis are needed in the corresponding population.

Data collection and analysis are needed in the corresponding population. The entire subjects contain in this study are spread over 13 Provinces (Henan province, Hebei province, Hunan Province etc.) and 2 autonomous regions (Inner Mongolia Autonomous Region and Guangxi Zhuang Autonomous Region).